Pharma channel feed

New bi­par­ti­san House bill in­cludes ma­jor PBM re­forms

Last year
Law

FDA main­tains Covid flex­i­bil­i­ties for IRB re­view of ex­pand­ed ac­cess drugs for in­di­vid­u­als

Last year
FDA+

Citius Phar­ma­ceu­ti­cals looks to re­file for­mer Ei­sai can­cer drug in ear­ly 2024

Last year
FDA+

Medicare en­rollees paid far more for drugs than plan spon­sors did in 2021, GAO says

Last year
FDA+

No­var­tis ad­justs busi­ness unit names in prepa­ra­tion for San­doz gener­ics and biosim­i­lars spin­off

Last year
Marketing

CDC en­cour­ages fall flu vac­ci­na­tions to tame symp­tom sever­i­ty in ‘Wild to Mild’ cam­paign

Last year
Marketing

MIT sci­en­tists look to un­lock po­ten­tial of ‘self-ad­ju­vant­i­ng’ mR­NA vac­cines in mice

Last year
R&D

Can No­vo Nordisk's block­buster weight loss drug and oth­er GLP-1s al­so work in NASH? The an­swer is com­pli­cat­ed

Last year
R&D
In Focus

Mer­ck to face FDA ad­comm in No­vem­ber over pre­vi­ous­ly re­ject­ed po­ten­tial chron­ic cough drug

Last year
FDA+

Bris­tol My­ers Squibb and Cel­gene named in class ac­tion suit over can­cer block­buster Po­m­a­lyst

Last year
Law

IPG Health de­buts new clin­i­cal tri­al di­ver­si­ty ap­proach based on ex­pe­ri­ence and spurred by phar­ma re­quests

Last year
Marketing

Phar­ma trade group and pa­tient or­ga­ni­za­tion pres­sure Con­gress with TV ad cam­paigns

Last year
Marketing

J&J shut­ters PhI­II tri­al for pul­monary hy­per­ten­sion drug, block­ing its ex­pand­ed use as patent ex­piry looms

Last year
R&D

Q&A: Bay­er on­col­o­gy head Chris­tine Roth talks strat­e­gy un­der new CEO

Last year

FDA ap­proves first gener­ics for Take­da’s Vy­vanse as AD­HD drug short­ages per­sist

Last year
FDA+

iP­SC biotech Shore­line Bio­sciences wins patent in­fringe­ment suit over Fate, White­head In­sti­tute

Last year
Cell/Gene Tx
Law

Cell­tri­on to build a $94M+ fa­cil­i­ty in South Ko­rea — re­port

Last year
Manufacturing

Court agrees with Ab­b­Vie’s method­ol­o­gy for dam­ages in Take­da case

Last year
Law

Janssen looks to turn PhI­II win for Ry­bre­vant in EGFR-mu­tat­ed NSCLC in­to pres­sure on As­traZeneca block­buster

Last year
R&D

How Bio­con Bi­o­log­ics is tak­ing on the US biosim­i­lars mar­ket

Last year
Marketing

Kriya Ther­a­peu­tics buys sci­en­tif­ic ad­vi­sor’s NASH gene ther­a­py com­pa­ny

Last year
Deals

Schott Phar­ma plans Frank­furt Stock Ex­change list­ing by end of year to boost of­fer­ing to in­jectable drug com­pa­nies

Last year
Financing
Manufacturing

FDA ten­ta­tive­ly ap­proves gener­ic ver­sion of pe­di­atric HIV drug un­der PEP­FAR pro­gram

Last year
FDA+

'F­DA is not a physi­cian,' ap­peals court rules in case against agen­cy's iver­mectin mes­sag­ing

Last year
FDA+
Law
First page Previous page 103104105106107108109 Next page Last page
A service from the Financial Times